What is Apogee Therapeutics?
Headquartered in Waltham, Massachusetts, Apogee Therapeutics operates as a clinical-stage biotechnology enterprise dedicated to the development of best-in-class antibody therapies. The company's core mission is to address the unmet needs of patients suffering from inflammatory and immunology (I&I) diseases. By focusing on the engineering of longer-acting molecules, Apogee aims to significantly reduce injection frequency, thereby improving patient adherence and therapeutic outcomes. The firm's market position is defined by its rigorous scientific methodology and its focus on high-prevalence conditions where current standards of care remain suboptimal.
How much funding has Apogee Therapeutics raised?
Apogee Therapeutics has raised a total of $1.4B across 2 funding rounds:
Series B
$149M
Unspecified
$1.3B
Series B (2022): $149M with participation from Deep Track Capital, Fidelity Management & Research Company, RTW Investments, and RA Capital Management
Unspecified (2026): $1.3B led by Blackstone
Key Investors in Apogee Therapeutics
Blackstone
Blackstone is a global investment firm that focuses on building and managing diversified asset portfolios across private equity, real estate, credit and strategic alternatives.
RTW Investments
RTW is a life sciences investment and innovation firm that focuses on biotech and medtech innovation throughout the entire lifecycle, from company creation to public companies.
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies.
What's next for Apogee Therapeutics?
With the successful closure of this major strategic investment, Apogee Therapeutics is well-positioned to accelerate its clinical development programs. The influx of capital will likely be deployed to scale manufacturing capabilities, expand clinical trial operations, and further validate the efficacy of its lead candidates. As the company transitions into more advanced stages of development, the focus will shift toward regulatory milestones and potential commercialization strategies. The continued support from specialized life sciences investors suggests a clear path toward establishing a dominant footprint in the immunology landscape, with the ultimate goal of delivering transformative medical solutions to patients globally.
See full Apogee Therapeutics company page
